铁死亡的机制及其在神经疾病中的作用
|
摘要
铁死亡是一种新型的细胞死亡方式,它在形态、生物化学和基因水平上,均不同于目前已知的细胞凋亡、自噬、坏死、角化和其他形式的细胞死亡。研究发现,铁死亡在神经、肿瘤等疾病中参与疾病的发生发展,并起到重要作用。阿尔茨海默病、帕金森综合征、亨廷顿舞蹈病、中风及脑室周围白质软化症等神经疾病,发病原因复杂,作用机制仍不明确。机制研究发现,铁死亡与神经疾病之间有着紧密联系,该文就铁死亡的机制及其在神经疾病发生发展过程中的作用进行综述。
Ferroptosis is distinct from apoptosis, autophagy,necrosis,cornification and other cell deaths from morphological,biochemical as well as genetic aspects. Ferroptosis plays a critical role in neurological diseases and cancers. Neurological diseases,such as Alzheimer 's disease, Parkinson 's disease,Huntington's disease,stroke,periventricular leukomalacia and so on,are characterized by multiple etiologies and mechanisms,and are potentially correlated with ferroptosis. Based on the recent researches on ferroptosis and neurological diseases,this review investigates ferroptosis and its role in neurological diseases.
Ferroptosis is distinct from apoptosis, autophagy,necrosis,cornification and other cell deaths from morphological,biochemical as well as genetic aspects. Ferroptosis plays a critical role in neurological diseases and cancers. Neurological diseases,such as Alzheimer 's disease, Parkinson 's disease,Huntington's disease,stroke,periventricular leukomalacia and so on,are characterized by multiple etiologies and mechanisms,and are potentially correlated with ferroptosis. Based on the recent researches on ferroptosis and neurological diseases,this review investigates ferroptosis and its role in neurological diseases.
引文
[1]Dixon S J,Lemberg K M,Lamprecht M R,et al.Ferroptosis:an iron-dependent form of nonapoptotic cell death[J].Cell,2012,149(5):1060-72.
[2]Kim D G,Hong Y H,Shin J Y,et al.Pattern of respiratory deterioration in sporadic amyotrophic lateral sclerosis according to onset lesion by using respiratory function tests[J].Exp Neurobiol,2015,24(4):351-7.
[3]Woo J H,Shimoni Y,Yang W S,et al.Elucidating compound mechanism of action by network perturbation analysis[J].Cell,2015,162(2):441-51.
[4]Wan S Y,Stockwell B R.Synthetic lethal screening identifies compounds activating iron-dependent,nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J].Cell Chem Biol,2008,15(3):234-45.
[5]Xie Y,Hou W,Song X,et al.Ferroptosis:process and function[J].Cell Death Differ,2016,23(3):369-79.
[6]Siddiq A,Aminova L R,Troy C M,et al.Selective inhibition of hypoxia-inducible factor(HIF)prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREBindependent pathways[J].J Neurosci,2009,29(27):8828-38.
[7]Eling N,Reuter L,Hazin J,et al.Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells[J].Oncosci,2015,2(5):517-32.
[8]Yang W S,Stockwell B R.Ferroptosis:death by lipid peroxidation[J].Trends Cell Biol,2015,26(3):165-76.
[9]Chang C F,Cho S,Wang J.(-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways[J].Ann Clin Transl Neurol,2014,1(4):258-71.
[10]Barayuga S M,Pang X,Andres M A,et al.Methamphetamine decreases levels of glutathione peroxidases 1 and 4 in SH-SY5Y neuronal cells:protective effects of selenium[J].Neurotoxicology,2013,37(1):240-6.
[11]Chen L,Hambright W S,Na R,et al.Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis[J].J Biol Chem,2015,290(47):28097-106.
[12]Johannesson T,Kristinsson J,Torsdottir G,et al.Ceruloplasmin(Cp)and iron in connection with Parkinson’s disease(PD)and Alzheimer’s disease(AD)[J].Laeknabladid,2012,98(10):531-7.
[13]Lewerenz J,Maher P.Chronic glutamate toxicity in neurodegenerative diseases——what is the evidence[J]?Front Neurosci,2015,9(469):1-20.
[14]Yagoda N,von Rechenberg M,Zaganjor E,et al.RAS-RAFMEK-dependent oxidative cell death involving voltage-dependent anion channels[J].Nature,2007,447(7146):864-8.
[15]姜懿纳,娄钰霞,张钊,等.Parkin相关疾病的研究进展[J].中国药理学通报,2016,32(4):455-8.[15]Jiang Y N,Lou Y X,Zhang Z,et al.Some diseases caused by Parkin[J].Chin Pharmacol Bull,2016,32(4):455-8.
[16]Rhodes S L,Buchanan D D,Ahmed I,et al.Pooled analysis of iron-related genes in Parkinson’s disease:association with transferrin[J].Neurobiol Dis,2014,62:172-8.
[17]Ayton S,Lei P,Hare D J,et al.Parkinson’s disease iron deposition caused by nitric oxide-induced loss ofβ-amyloid precursor protein[J].J Neurosci,2015,35(8):3591-7.
[18]Devos D,Moreau C,Devedjian J C,et al.Targeting chelatable iron as a therapeutic modality in Parkinson’s disease[J].Antioxid Redox Signal,2014,21(2):195-210.
[19]Brauer R,Bhaskaran K,Chaturvedi N,et al.Glitazone treatment and incidence of Parkinson’s disease among people with diabetes:a retrospective cohort study[J].PLo S Med,2015,12(7):e1001854.
[20]Hare D J,Lei P,Ayton S,et al.An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta[J].Chem Sci,2014,5(6):2160-9.
[21]Do Van B,Gouel F,Jonneaux A,et al.Ferroptosis,a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC[J].Neurobiol Dis,2016,94:169-78.
[22]Johnson W M,Wilson-Delfosse A L,Mieyal J J.Dysregulation of glutathione homeostasis in neurodegenerative diseases[J].Nutrients,2012,4(10):1399-440.
[23]Skouta R,Dixon S J,Wang J,et al.Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models.[J].J Am Chem Soc,2014,136(12):4551-6.
[24]宋修云,胡金凤,陈乃宏.神经细胞凋亡与脑缺血疾病[J].中国药理学通报,2012,28(3):307-10.[24]Song X Y,Hu J F,Chen N H.Neurons apoptosis and cerebral ischemia[J].Chin Pharmacol Bull,2012,28(3):307-10.
[2]Kim D G,Hong Y H,Shin J Y,et al.Pattern of respiratory deterioration in sporadic amyotrophic lateral sclerosis according to onset lesion by using respiratory function tests[J].Exp Neurobiol,2015,24(4):351-7.
[3]Woo J H,Shimoni Y,Yang W S,et al.Elucidating compound mechanism of action by network perturbation analysis[J].Cell,2015,162(2):441-51.
[4]Wan S Y,Stockwell B R.Synthetic lethal screening identifies compounds activating iron-dependent,nonapoptotic cell death in oncogenic-RAS-harboring cancer cells[J].Cell Chem Biol,2008,15(3):234-45.
[5]Xie Y,Hou W,Song X,et al.Ferroptosis:process and function[J].Cell Death Differ,2016,23(3):369-79.
[6]Siddiq A,Aminova L R,Troy C M,et al.Selective inhibition of hypoxia-inducible factor(HIF)prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREBindependent pathways[J].J Neurosci,2009,29(27):8828-38.
[7]Eling N,Reuter L,Hazin J,et al.Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells[J].Oncosci,2015,2(5):517-32.
[8]Yang W S,Stockwell B R.Ferroptosis:death by lipid peroxidation[J].Trends Cell Biol,2015,26(3):165-76.
[9]Chang C F,Cho S,Wang J.(-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways[J].Ann Clin Transl Neurol,2014,1(4):258-71.
[10]Barayuga S M,Pang X,Andres M A,et al.Methamphetamine decreases levels of glutathione peroxidases 1 and 4 in SH-SY5Y neuronal cells:protective effects of selenium[J].Neurotoxicology,2013,37(1):240-6.
[11]Chen L,Hambright W S,Na R,et al.Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis[J].J Biol Chem,2015,290(47):28097-106.
[12]Johannesson T,Kristinsson J,Torsdottir G,et al.Ceruloplasmin(Cp)and iron in connection with Parkinson’s disease(PD)and Alzheimer’s disease(AD)[J].Laeknabladid,2012,98(10):531-7.
[13]Lewerenz J,Maher P.Chronic glutamate toxicity in neurodegenerative diseases——what is the evidence[J]?Front Neurosci,2015,9(469):1-20.
[14]Yagoda N,von Rechenberg M,Zaganjor E,et al.RAS-RAFMEK-dependent oxidative cell death involving voltage-dependent anion channels[J].Nature,2007,447(7146):864-8.
[15]姜懿纳,娄钰霞,张钊,等.Parkin相关疾病的研究进展[J].中国药理学通报,2016,32(4):455-8.[15]Jiang Y N,Lou Y X,Zhang Z,et al.Some diseases caused by Parkin[J].Chin Pharmacol Bull,2016,32(4):455-8.
[16]Rhodes S L,Buchanan D D,Ahmed I,et al.Pooled analysis of iron-related genes in Parkinson’s disease:association with transferrin[J].Neurobiol Dis,2014,62:172-8.
[17]Ayton S,Lei P,Hare D J,et al.Parkinson’s disease iron deposition caused by nitric oxide-induced loss ofβ-amyloid precursor protein[J].J Neurosci,2015,35(8):3591-7.
[18]Devos D,Moreau C,Devedjian J C,et al.Targeting chelatable iron as a therapeutic modality in Parkinson’s disease[J].Antioxid Redox Signal,2014,21(2):195-210.
[19]Brauer R,Bhaskaran K,Chaturvedi N,et al.Glitazone treatment and incidence of Parkinson’s disease among people with diabetes:a retrospective cohort study[J].PLo S Med,2015,12(7):e1001854.
[20]Hare D J,Lei P,Ayton S,et al.An iron-dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta[J].Chem Sci,2014,5(6):2160-9.
[21]Do Van B,Gouel F,Jonneaux A,et al.Ferroptosis,a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC[J].Neurobiol Dis,2016,94:169-78.
[22]Johnson W M,Wilson-Delfosse A L,Mieyal J J.Dysregulation of glutathione homeostasis in neurodegenerative diseases[J].Nutrients,2012,4(10):1399-440.
[23]Skouta R,Dixon S J,Wang J,et al.Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models.[J].J Am Chem Soc,2014,136(12):4551-6.
[24]宋修云,胡金凤,陈乃宏.神经细胞凋亡与脑缺血疾病[J].中国药理学通报,2012,28(3):307-10.[24]Song X Y,Hu J F,Chen N H.Neurons apoptosis and cerebral ischemia[J].Chin Pharmacol Bull,2012,28(3):307-10.